NEW: Premarket Now Starts at 4AM!

We’re excited to announce the extension of premarket and aftermarket hours! Our members now have access to quotes daily from 4:00 AM to 8:00 PM ET — offering greater flexibility and deeper insights into market trends beyond regular trading hours.

Upgrade to FINVIZ*Elite to access premarket quotes »

MNMD

Mind Medicine Inc

Apr 17 • 04:00PM ET

5.77

Dollar change +0.31
Percentage change 5.68	%

Healthcare • Biotechnology • USA • NASD

Peers: ATAI CYBN CMPS GHRS RLAY RLMD PLRX VTGN FBRX

| Held by: IWM VXF IWO VTWO SCHA XPH VHT IHE IWC PSIL

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-1.54	Insider Own	1.20%	Shs Outstand	75.37M	Perf Week	12.26%
Market Cap	434.88M	Forward P/E	-	EPS next Y	-1.77	Insider Trans	-6.90%	Shs Float	74.09M	Perf Month	-13.88%
Income	-108.70M	PEG	-	EPS next Q	-0.37	Inst Own	49.60%	Short Float	15.30%	Perf Quarter	-11.37%
Sales	-	P/S	-	EPS this Y	36.90%	Inst Trans	-17.91%	Short Ratio	5.75	Perf Half Y	-2.45%
Book/sh	3.21	P/B	1.80	EPS next Y	-10.44%	ROA	-50.90%	Short Interest	11.34M	Perf Year	-41.60%
Cash/sh	3.63	P/C	1.59	EPS next 5Y	-	ROE	-68.00%	52W Range	4.70 - 10.44	Perf YTD	-17.10%
Dividend Est.	-	P/FCF	-	EPS past 5Y	10.40%	ROI	-	52W High	-44.71%	Beta	2.79
Dividend TTM	-	Quick Ratio	7.00	Sales past 5Y	-	Gross Margin	-	52W Low	22.77%	ATR (14)	0.54
Dividend Ex-Date	-	Current Ratio	7.20	EPS Y/Y TTM	-51.01%	Oper. Margin	-	RSI (14)	47.34	Volatility	7.42% 9.05%
Employees	74	Debt/Eq	0.09	Sales Y/Y TTM	-	Profit Margin	-	Recom	-	Target Price	24.00
Option/Short	Yes / Yes	LT Debt/Eq	0.09	EPS Q/Q	30.30%	Payout	-	Rel Volume	0.59	Prev Close	5.46
Sales Surprise	-	EPS Surprise	-39.93%	Sales Q/Q	-	Earnings	Mar 06 BMO	Avg Volume	1.97M	Price	5.77
SMA20	-1.29%	SMA50	-13.75%	SMA200	-16.34%	Trades		Volume	1,166,483	Change	5.68%

Date	Action	Analyst	Rating Change	Price Target Change
Jan-28-25	Initiated	Evercore ISI	Outperform	$23
Dec-20-24	Initiated	Chardan Capital Markets	Buy	$20
Oct-14-24	Resumed	Leerink Partners	Outperform	$20
Jul-24-24	Initiated	ROTH MKM	Buy	$36
May-29-24	Initiated	Robert W. Baird	Outperform	$27
Apr-15-24	Initiated	Leerink Partners	Outperform	$20
Dec-05-23	Initiated	Canaccord Genuity	Buy	$9
Dec-09-22	Resumed	ROTH Capital	Buy	$25
Nov-16-22	Initiated	RBC Capital Mkts	Outperform	$5
Aug-26-22	Initiated	Oppenheimer	Outperform	$3.50
Aug-10-22	Initiated	Cantor Fitzgerald	Overweight	$3
May-04-22	Initiated	ROTH Capital	Buy	$7
Jun-28-21	Initiated	Maxim Group	Buy	$6

Show Previous Ratings

Apr-15-25 07:00AM	MindMed Announces First Patient Dosed in Phase 3 Emerge Study of MM120 in Major Depressive Disorder (MDD) (Business Wire)
Mar-24-25 04:01PM	MindMed Announces New Employee Inducement Grants (Business Wire)
Mar-22-25 10:30AM	Psychedelic: Exclusive talk with biotech company Clearmind Medicine (TipRanks)
Mar-21-25 11:50AM	Psychedelic: atai Life Sciences, NRx report quarterly results (TipRanks)
Mar-17-25 07:00AM	MindMed Appoints Matt Wiley as Chief Commercial Officer (Business Wire)
11:40AM	Loading…
Mar-14-25 11:40AM	Psychedelic: atai reports dosing of first patient in Phase 2 VLS-01 trial (TipRanks)
Mar-06-25 07:00AM	MindMed Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Business Updates (Business Wire)
Mar-04-25 07:00AM	MindMed to Present at Leerink's Global Healthcare Conference 2025 (Business Wire)
Feb-28-25 11:30AM	Psychedelic: GH Research, Compass Pathways report earnings results (TipRanks)
Feb-20-25 07:00AM	MindMed to Report Fourth Quarter and Full Year 2024 Financial Results on March 6, 2025 (Business Wire)
Feb-13-25 04:14PM	It's Official: The Senate Will Let Robert F. Kennedy Jr. 'Go Wild' On Health Care (Investor's Business Daily) +14.34%
Feb-12-25 01:25PM	RFK Jr. Confirmation Looms. How Kennedy Could 'Go Wild' On Health Care. (Investor's Business Daily)
Feb-04-25 07:00AM	MindMed to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference (Business Wire) +10.85%
Jan-31-25 07:20AM	Mind Medicine doses first patient in Panorama study (TipRanks)
Jan-30-25 07:00AM	MindMed Announces First Patient Dosed in Panorama, the Second Pivotal Phase 3 Study of MM120 in Generalized Anxiety Disorder (Business Wire)
10:48AM	Loading…
Jan-20-25 10:48AM	Weekly Roundup on the Cannabis Sector & Psychedelic Sector (Market Exclusive)
Dec-19-24 07:00AM	MindMed to Be Added to the Nasdaq Biotechnology Index (Business Wire)
Dec-16-24 07:00AM	MindMed Announces First Patient Dosed in Phase 3 Voyage Study of MM120 in Generalized Anxiety Disorder (GAD) (Business Wire)
Dec-11-24 07:00AM	MindMed Scientific Presentations at American College of Neuropsychopharmacology (ACNP) 2024 Congress (Business Wire)
Dec-05-24 07:00AM	MindMed Awarded Innovation Passport Designation by the United Kingdom (UK) Innovative Licensing and Access Pathway (ILAP) Steering Group for MM120 Orally Disintegrating Tablet (ODT) for Generalized Anxiety Disorder (GAD) (Business Wire)
Dec-03-24 07:00AM	MindMed Appoints Javier Muniz, M.D., as Vice President of Research and Development Strategy (Business Wire) -7.99%
Dec-02-24 07:00AM	MindMed Announces New Employee Inducement Grants (Business Wire)
Nov-18-24 07:00AM	MindMed Appoints Gregg Pratt, Ph.D. as Chief Regulatory and Quality Assurance Officer (Business Wire) -11.86%
Nov-13-24 07:00AM	MindMed to Participate in Upcoming Investor Conferences (Business Wire)
Nov-07-24 04:01PM	MindMed Reports Third Quarter 2024 Financial Results and Business Updates (Business Wire) +11.41% +12.90%
Oct-24-24 07:00AM	MindMed to Host Conference Call and Webcast to Discuss Third Quarter 2024 Financial Results and Provide Business Update (Business Wire)
Oct-12-24 06:05PM	Mind Medicine assumed with an Outperform at Leerink (TipRanks)
Sep-09-24 04:01PM	MindMed Announces New Employee Inducement Grants (Business Wire)
Sep-04-24 07:00AM	MindMed to Participate in September Investor Conferences (Business Wire) +5.86%
Aug-13-24 07:00AM	MindMed Reports Second Quarter 2024 Financial Results and Business Updates (Business Wire)
09:02PM	Loading…
Aug-12-24 09:02PM	Weekly Roundup on the Cannabis Sector & Psychedelic Sector (Market Exclusive)
Aug-09-24 08:44AM	Mind Medicine (MindMed) Inc. Announces Pricing of Public Offering (Business Wire) -10.03%
06:00AM	Mind Medicine (MindMed) Inc. Announces Proposed Public Offering (Business Wire)
Aug-06-24 04:01PM	MindMed to Present at Canaccord Genuitys 44th Annual Growth Conference (Business Wire)
07:00AM	MindMed to Host Conference Call and Webcast to Discuss Second Quarter 2024 Financial Results and Provide Business Update (Business Wire)
Jul-29-24 07:00AM	MindMed Appoints Stephanie Fagan as Chief Corporate Affairs Officer (Business Wire)
Jul-17-24 07:00AM	MindMed Announces Issuance of New Patent for MM120 Orally Disintegrating Tablet (ODT) (Business Wire)
Jul-06-24 07:21AM	3 Psychedelic Stocks to Ride to the Moon and Beyond (InvestorPlace)
Jul-04-24 02:13PM	FDA Favorites: 3 Biotech Stocks on the Verge of Major Approvals (InvestorPlace)
Jun-28-24 07:00AM	MindMed to be Included in Russell 2000 and Russell 3000 Indexes (Business Wire)
Jun-21-24 07:00AM	MindMed to Present at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference (Business Wire)
Jun-20-24 07:00AM	MindMed Announces Constructive End-of-Phase 2 Meeting with U.S. FDA for MM120 in Generalized Anxiety Disorder (GAD) (Business Wire)
Jun-18-24 12:31PM	Wall Street Favorites: 3 Penny Stocks With Strong Buy Ratings for June 2024 (InvestorPlace)
Jun-14-24 09:40AM	Is Mind Medicine MindMed (MNMD) Outperforming Other Medical Stocks This Year? (Zacks)
Jun-05-24 11:42AM	Psychedelic Drug Stocks Plummet On FDA Advisers' Doubts About Ecstasy Candidate (The Wall Street Journal) -10.06%
May-29-24 09:40AM	Are Medical Stocks Lagging Mind Medicine MindMed (MNMD) This Year? (Zacks) +6.64%
May-28-24 07:00AM	MindMed to Participate in June Conferences (Business Wire)
May-23-24 03:41PM	The Time Traveler's Portfolio: 3 Stocks to Buy Now for Massive Returns by 2034 (InvestorPlace) -5.36%
May-18-24 09:32AM	Jim Cramer's Latest Stock Picks in May 2024 (Insider Monkey)
May-10-24 11:00AM	Top Russell 2000 Picks: 3 Small-Cap Stocks to Scoop Up This May (InvestorPlace)
May-09-24 04:01PM	MindMed to Participate at May Investor Conferences (Business Wire) -5.10%
08:00AM	New Studies Presented at the International Society for Health Economics and Outcomes Research Meeting (ISPOR 24) Show Growing Burden and Impact of Generalized Anxiety Disorder (GAD) in the US (Business Wire)
06:49AM	Biotech Breakthroughs: 3 Stocks on the Verge of Revolutionizing Medicine (InvestorPlace)
May-08-24 09:00PM	MNMD Stock Earnings: Mind Medicine Misses EPS for Q1 2024 (InvestorPlace)
04:01PM	MindMed Reports First Quarter 2024 Financial Results and Business Updates (Business Wire)
May-04-24 08:00AM	MindMed Presents Phase 2b Study of MM120 for Generalized Anxiety Disorder (GAD) at American Psychiatric Association (APA) Annual Meeting in New York (Business Wire)
May-02-24 07:00AM	MindMed to Host Conference Call and Webcast to Discuss First Quarter 2024 Financial Results and Provide Business Update (Business Wire)
Apr-25-24 07:00AM	MindMed to Present at Upcoming May Medical Conferences (Business Wire)
Apr-08-24 06:59AM	MindMed (MNMD) Stock Rises 154% in 3 Months: Here's Why (Zacks)
Apr-02-24 07:00AM	MindMed to Present at Upcoming April Medical Conferences (Business Wire)
Apr-01-24 05:00PM	MindMed Announces Voluntary Delisting from Cboe Canada (Business Wire)
Mar-19-24 08:00AM	The Next Great Biotech Boom Has Arrived (PR Newswire)
Mar-11-24 07:00AM	MindMed to Participate in the Leerink Partners 2024 Global Biopharma Conference (Business Wire) -14.02%
Mar-10-24 11:10AM	Weekly Roundup on the Cannabis Sector & Psychedelic Sector (Market Exclusive)
Mar-08-24 10:46AM	MindMed's (MNMD) Anxiety Drug Gets FDA Breakthrough Therapy Tag (Zacks) +7.78%
07:00AM	Numinus Wellness Congratulates MindMed on Positive Results from Phase 2B Clinical Trials of MM120 for Generalized Anxiety Disorder (PR Newswire)
Mar-07-24 07:13AM	Mind Medicine (MindMed) Inc. Announces Pricing of Underwritten Offering of Common Shares and Concurrent Private Placement (Business Wire) +51.52%
06:00AM	MindMed Receives FDA Breakthrough Therapy Designation and Announces Positive 12-Week Durability Data From Phase 2B Study of MM120 for Generalized Anxiety Disorder (Business Wire)
Mar-01-24 09:00AM	MindMed to Host Conference Call and Webcast to Discuss Data Update for MM120 (Business Wire) +9.01%
Feb-28-24 07:05AM	MindMed Reports 2023 Financial Results and Business Updates (Business Wire)
Feb-22-24 07:00AM	MindMed to Host Conference Call and Webcast to Discuss 2023 Financial Results and Provide Business Update (Business Wire)
Feb-07-24 07:00AM	MindMed to Participate in the 34th Annual Oppenheimer Healthcare Life Sciences Conference (Business Wire)
Jan-24-24 09:00AM	How Psychedelic-Based Therapeutics Are Advancing in Treating Generalized Anxiety Disorder (GAD) Condition (PR Newswire) -5.59%
Jan-08-24 12:27PM	Canadian Investment Regulatory Organization Trading Halt - MMED.WR (PR Newswire) +7.33%
07:45AM	MindMed Announces Business Update and Anticipated Milestones for 2024 (Business Wire)
Dec-17-23 05:49PM	Weekly Roundup on the Cannabis Sector & Psychedelic Sector (Market Exclusive)
Dec-14-23 07:30AM	MindMed Announces Positive Topline Results from Phase 2b Trial of MM-120 in Generalized Anxiety Disorder (Business Wire) +11.46%
Dec-11-23 12:19PM	Canadian Investment Regulatory Organization Trading Halt - MMED.WA (PR Newswire)
Nov-02-23 04:01PM	MindMed Reports Third Quarter 2023 Financial Results and Business Highlights (Business Wire) +8.43% +14.44%
Oct-30-23 12:11PM	Canadian Investment Regulatory Organization Trading Halt - MMED.WS (PR Newswire)
Oct-26-23 07:30AM	MindMed to Host Conference Call and Webcast to Discuss Third Quarter 2023 Financial Results and Provide Business Update (Business Wire)
Oct-24-23 07:30AM	MindMed Completes Enrollment of Phase 2a Trial of MM-120 in Adults with Attention-Deficit/Hyperactivity Disorder (ADHD) (Business Wire)
Oct-03-23 07:30AM	MindMed to Present Data on the Preclinical Activity of MM-402 at the 36th Annual European College of Neuropsychopharmacology (ECNP) Congress (Business Wire)
Sep-14-23 07:30AM	MindMed to Participate in the TD Cowen 3rd Annual Novel Mechanisms in Neuropsychiatry Summit (Business Wire) +6.42%
Sep-12-23 07:30AM	MindMed Completes Enrollment of Phase 2b Trial of MM-120 in Generalized Anxiety Disorder (GAD) (Business Wire)
Aug-28-23 07:30AM	MindMed to Participate at September Investor Conferences (Business Wire)
Aug-14-23 07:30AM	MindMed Secures $50.0 Million Credit Facility with K2 HealthVentures (Business Wire)
Aug-03-23 04:01PM	MindMed Reports Second Quarter 2023 Financial Results and Business Highlights (Business Wire) -7.64%
07:30AM	MindMed Announces Exclusive License Agreement With Catalent for Its Patented Zydis® Fast-Dissolve Technology for Use with MM-120 (Business Wire)
Jul-31-23 08:30AM	MindMed to Host Conference Call and Webcast to Discuss Second Quarter 2023 Financial Results and Provide Business Update (Business Wire) +13.07%
Jun-22-23 08:42AM	FCM Received Significant Support from Shareholders, Disappointed that Passive Investors Saw Fit to Give Incumbent Directors Another Chance to Disappoint (GlobeNewswire)
08:30AM	MindMed to Participate in the H.C. Wainwright 4th Annual Neuropsychiatry Virtual Conference (Business Wire)
Jun-21-23 12:08PM	MindMed Announces Election of All Six Company Nominees at Annual Meeting (Business Wire)
Jun-20-23 08:30AM	MindMed Provides Overview of Clinical Progress and Corporate Updates at Investor Day (Business Wire)
Jun-15-23 04:23PM	FCM Denounces MindMeds Manipulation of Corporate Machinery to Protect Incumbent Board of Directors (GlobeNewswire)
10:45AM	MindMed Adjourns Annual General Meeting of Shareholders (Business Wire)
Jun-09-23 09:00AM	MindMed Urges Shareholders to Vote TODAY for Company Nominees Ahead of June 13th Deadline (Business Wire)
Jun-08-23 11:30AM	Leading Proxy Advisory Firm Glass Lewis Recommends MindMed Shareholders Vote FOR All Six Company Nominees (Business Wire)
Jun-07-23 08:07AM	FCM Plans for MM-120 (LSD) FDA Approval in 2026 And Extends Share Lockup Until June 15, 2026 (GlobeNewswire)
08:00AM	MindMed to Host Investor Day June 2023 (Business Wire)

Mind Medicine (MindMed) Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company's lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and MM402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase I clinical trials for the treatment of core symptoms of autism spectrum disorder. Mind Medicine (MindMed) Inc. is headquartered in New York, New York.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Barrow Robert	Chief Executive Officer	Mar 25 '25	Sale	6.74	21,208	142,942	856,556	Mar 26 05:00 PM
Karlin Daniel	Chief Medical Officer	Mar 25 '25	Sale	6.74	6,836	46,075	446,177	Mar 26 05:00 PM
Sullivan Mark	Chief Legal Officer	Mar 25 '25	Sale	6.74	6,576	44,322	316,621	Mar 26 05:00 PM
Liao Carrie	Chief Accounting Officer	Mar 25 '25	Sale	6.74	2,347	15,819	144,923	Mar 26 05:00 PM
MARK SULLIVAN	Officer	Mar 25 '25	Proposed Sale	6.74	6,576	44,304		Mar 25 04:11 PM
CARRIE LIAO	Officer	Mar 25 '25	Proposed Sale	6.74	2,347	15,812		Mar 25 04:09 PM
ROBERT B BARROW	Officer	Mar 25 '25	Proposed Sale	6.74	21,208	142,883		Mar 25 04:06 PM
DANIEL ROLLINGS KARLIN	Officer	Mar 25 '25	Proposed Sale	6.74	6,836	46,056		Mar 25 04:03 PM
Barrow Robert	Chief Executive Officer	Dec 26 '24	Sale	7.43	19,106	141,958	526,666	Dec 27 04:31 PM
Liao Carrie	Chief Accounting Officer	Dec 26 '24	Sale	7.43	2,273	16,888	97,270	Dec 27 04:31 PM
Karlin Dan	Chief Medical Officer	Dec 26 '24	Sale	7.43	6,643	49,357	338,013	Dec 27 04:30 PM
Sullivan Mark	Chief Legal Officer	Dec 26 '24	Sale	7.43	4,519	33,576	173,197	Dec 27 04:30 PM
ROBERT B BARROW	Officer	Dec 26 '24	Proposed Sale	7.43	19,106	141,979		Dec 26 04:39 PM
MARK SULLIVAN	Officer	Dec 26 '24	Proposed Sale	7.43	4,519	33,581		Dec 26 04:31 PM
DAN ROLLINGS KARLIN	Officer	Dec 26 '24	Proposed Sale	7.43	6,643	49,365		Dec 26 04:30 PM
CARRIE LIAO	Officer	Dec 26 '24	Proposed Sale	7.43	2,273	16,891		Dec 26 04:28 PM
GRYSKA DAVID W	Director	Dec 05 '24	Buy	7.17	2,500	17,925	19,851	Dec 05 04:30 PM
Sullivan, Mark	Officer	Sep 25 '24	Proposed Sale	5.98	4,430	26,487		Sep 25 08:31 PM
Liao Carrie	Chief Accounting Officer	Sep 25 '24	Sale	5.98	2,352	14,065	99,543	Sep 25 08:30 PM
Barrow Robert	Chief Executive Officer	Sep 25 '24	Sale	5.98	19,771	118,231	545,772	Sep 25 08:29 PM
Karlin, Dan	Officer	Sep 25 '24	Proposed Sale	5.98	6,871	41,081		Sep 25 08:29 PM
Karlin Dan	Chief Medical Officer	Sep 25 '24	Sale	5.98	6,871	41,089	344,656	Sep 25 08:29 PM
Sullivan Mark	Chief Legal Officer	Sep 25 '24	Sale	5.98	4,430	26,491	177,716	Sep 25 08:28 PM
Barrow, Robert	Officer, Director	Sep 25 '24	Proposed Sale	5.98	19,771	118,210		Sep 25 08:27 PM
GRYSKA DAVID W	Director	Aug 23 '24	Buy	5.98	3,500	20,930	17,351	Aug 26 07:00 PM
Halperin Wernli Miri	Executive President	Aug 21 '24	Option Exercise	3.70	50,000	185,000	235,000	Aug 22 04:30 PM
Barrow Robert	Chief Executive Officer	Aug 19 '24	Buy	6.31	500	3,155	565,043	Aug 20 09:14 PM
Barrow Robert	Chief Executive Officer	Aug 20 '24	Buy	6.12	500	3,060	565,543	Aug 20 09:14 PM
Karlin Dan	Chief Medical Officer	Jun 25 '24	Sale	7.22	6,925	49,998	351,527	Jun 25 07:00 PM
Sullivan Mark	Chief Legal Officer	Jun 25 '24	Sale	7.22	17,854	128,906	182,146	Jun 25 07:00 PM
Barrow Robert	Chief Executive Officer	Jun 25 '24	Sale	7.22	15,659	113,058	564,543	Jun 25 07:00 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

MNMD

Mind Medicine Inc

Upgrade your FINVIZ experience